New chemo combo tested for Tough-to-Treat blood cancers
NCT ID NCT03896269
Summary
This early-stage study is testing a new chemotherapy combination called CPX-351 in adults with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or hasn't responded to standard treatments. The main goals are to find the safest dose and understand the side effects. Researchers will also look for early signs that the treatment can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.